{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:36:10Z","timestamp":1785900970273,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vascn.2023.107251","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T02:07:04Z","timestamp":1676254024000},"page":"107251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Disconnect between COX-2 selective inhibition and cardiovascular risk in preclinical models"],"prefix":"10.1016","volume":"120","author":[{"given":"Yevgeniya E.","family":"Koshman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L.","family":"Bielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandan M.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Kowalkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lai-Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathap Kumar","family":"Mahalingaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nari N.","family":"Talaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda S.","family":"Wilsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Zafiratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry R.","family":"Van Vleet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vascn.2023.107251_bb9063","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1211\/0022357021387","article-title":"Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects","volume":"55","author":"Ahuja","year":"2003","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.vascn.2023.107251_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/09629350210311","article-title":"The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase","volume":"11","author":"Akarasereenont","year":"2002","journal-title":"Mediators of Inflammation"},{"issue":"6","key":"10.1016\/j.vascn.2023.107251_bb0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/09629359990298","article-title":"The induction of cyclooxygenase-2 in IL-1beta-treated endothelial cells is inhibited by prostaglandin E2 through cAMP","volume":"8","author":"Akarasereenont","year":"1999","journal-title":"Mediators of Inflammation"},{"issue":"5","key":"10.1016\/j.vascn.2023.107251_bb0015","first-page":"590","article-title":"Platelet aggregation in rhesus macaques (Macaca mulatta) in response to short-term meloxicam administration","volume":"52","author":"Anderson","year":"2013","journal-title":"Journal of the American Association for Laboratory Animal Science"},{"issue":"5","key":"10.1016\/j.vascn.2023.107251_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020062","article-title":"Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse","volume":"6","author":"Armstrong","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vascn.2023.107251_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117631","article-title":"Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review","volume":"251","author":"Arora","year":"2020","journal-title":"Life Sciences"},{"issue":"21","key":"10.1016\/j.vascn.2023.107251_bb0030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group","volume":"343","author":"Bombardier","year":"2000","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.vascn.2023.107251_bb0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jacc.2006.03.053","article-title":"Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation","volume":"48","author":"Borgdorff","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1016\/j.vascn.2023.107251_bb0040","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: The use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"3","key":"10.1016\/j.vascn.2023.107251_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2460\/ajvr.68.3.251","article-title":"Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs","volume":"68","author":"Brainard","year":"2007","journal-title":"American Journal of Veterinary Research"},{"issue":"11","key":"10.1016\/j.vascn.2023.107251_bb0050","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.vascn.2023.107251_bb0055","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1124\/mol.109.057844","article-title":"Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles","volume":"76","author":"Brueggemann","year":"2009","journal-title":"Molecular Pharmacology"},{"issue":"Suppl 3A","key":"10.1016\/j.vascn.2023.107251_bb0060","article-title":"Cyclooxygenase inhibition and thrombogenicity","volume":"110","author":"Catella-Lawson","year":"2001","journal-title":"The American Journal of Medicine"},{"issue":"2","key":"10.1016\/j.vascn.2023.107251_bb0065","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(24)38195-9","article-title":"Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids","volume":"289","author":"Catella-Lawson","year":"1999","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2023.107251_bb0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharep.2013.12.011","article-title":"Pharmacological characterization of carrageenan induced heat muscle hyperalgesia in rats using non-selective, preferential and selective COX-2 inhibitors","volume":"66","author":"Chopade","year":"2014","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.vascn.2023.107251_bb0075","series-title":"Instruction Manual for the Chrono-Log\u00ae Model 700 Whole blood Lumiaggregometer","author":"Chrono-Log\u00ae","year":"2023"},{"issue":"2","key":"10.1016\/j.vascn.2023.107251_bb0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.ATV.0000104005.92603.f2","article-title":"Cyclooxygenase-2 expression and inhibition in atherothrombosis","volume":"24","author":"Cipollone","year":"2004","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"3","key":"10.1016\/j.vascn.2023.107251_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/03009749709065673","article-title":"Activation of endothelial cells in thrombosis and vasculitis","volume":"26","author":"Cockwell","year":"1997","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"6","key":"10.1016\/j.vascn.2023.107251_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.vascn.2023.107251_bb0095","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tvjl.2004.04.003","article-title":"Effects of preoperative administration of meloxicam on whole blood platelet aggregation, buccal mucosal bleeding time, and haematological indices in dogs undergoing elective ovariohysterectomy","volume":"170","author":"Fresno","year":"2005","journal-title":"Veterinary Journal"},{"key":"10.1016\/j.vascn.2023.107251_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2014.02.032","article-title":"Celecoxib and ion channels: A story of unexpected discoveries","volume":"730","author":"Frolov","year":"2014","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.vascn.2023.107251_bb0105","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","article-title":"COX-2 inhibitors and cardiovascular risk","volume":"50","author":"Funk","year":"2007","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"6 Suppl 1","key":"10.1016\/j.vascn.2023.107251_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0049-0172(97)80049-2","article-title":"Meloxicam: Selective COX-2 inhibition in clinical practice","volume":"26","author":"Furst","year":"1997","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"6","key":"10.1016\/j.vascn.2023.107251_bb0115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/heart.86.6.649","article-title":"Patients with acute coronary syndromes express enhanced CD40 ligand\/CD154 on platelets","volume":"86","author":"Garlichs","year":"2001","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.vascn.2023.107251_bb0120","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1538-7836.2007.02782.x","article-title":"Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers","volume":"5","author":"Graff","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"12 Pt 2","key":"10.1016\/j.vascn.2023.107251_bb0125","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/009127000004001224","article-title":"A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers","volume":"40","author":"Greenberg","year":"2000","journal-title":"Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1016\/j.vascn.2023.107251_bb0130","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1073\/pnas.72.8.2994","article-title":"Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides","volume":"72","author":"Hamberg","year":"1975","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/j.vascn.2023.107251_bb0135","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1440-1681.2006.04464.x","article-title":"Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent","volume":"33","author":"Harirforoosh","year":"2006","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"issue":"2","key":"10.1016\/j.vascn.2023.107251_bb0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.300.2.367","article-title":"Cyclooxygenase-2--10 years later","volume":"300","author":"Hinz","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2023.107251_bb0145","doi-asserted-by":"crossref","first-page":"F294","DOI":"10.1152\/ajprenal.00347.2001","article-title":"Role of prostanoids in regulation of the renin-angiotensin-aldosterone system by salt intake","volume":"283","author":"H\u00f6cherl","year":"2002","journal-title":"American Journal of Physiology. Renal Physiology"},{"issue":"7141","key":"10.1016\/j.vascn.2023.107251_bb0150","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/bmj.316.7141.1328","article-title":"Endothelial cell activation. A central pathophysiological process","volume":"316","author":"Hunt","year":"1998","journal-title":"Bmj"},{"issue":"95","key":"10.1016\/j.vascn.2023.107251_bb0155","first-page":"52324","article-title":"Measurement of smooth muscle function in the isolated tissue bath-applications to pharmacology research","volume":"Exp","author":"Jespersen","year":"2015","journal-title":"Journal of Vision"},{"issue":"1","key":"10.1016\/j.vascn.2023.107251_bb0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/rvsc.1999.0331","article-title":"Optimal conditions for simultaneous measurement of platelet aggregation and ATP secretion in canine whole blood","volume":"68","author":"J\u00fcttner","year":"2000","journal-title":"Research in Veterinary Science"},{"issue":"2","key":"10.1016\/j.vascn.2023.107251_bb0165","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1073\/pnas.1517642113","article-title":"Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-\u03baB and NFAT transcriptional pathways","volume":"113","author":"Kirkby","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.vascn.2023.107251_bb0170","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V110.11.2098.2098","article-title":"No effect of Etodolac, a COX inhibitor, on platelet function in healthy volunteers","volume":"110","author":"Korte","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.vascn.2023.107251_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.vascn.2018.01.002","article-title":"The evaluation of drug-induced changes in left ventricular function in pentobarbital-anesthetized dogs","volume":"91","author":"Koshman","year":"2018","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107251_bb0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/00912700022008766","article-title":"Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial","volume":"40","author":"Leese","year":"2000","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2023.107251_bb0185","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.vascn.2017.02.020","article-title":"Potential functional and pathological side effects related to off-target pharmacological activity","volume":"87","author":"Lynch","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2023.107251_bb0190","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1365-2141.1999.01399.x","article-title":"Thrombosis and bleeding in myeloproliferative disorders: Identification of at-risk patients with whole blood platelet aggregation studies","volume":"105","author":"Manoharan","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1016\/j.vascn.2023.107251_bb0195","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ajh.20698","article-title":"Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders","volume":"81","author":"Manoharan","year":"2006","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1016\/j.vascn.2023.107251_bb0200","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.vascn.2023.107251_bb0205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/cp.1999.v66.a101063","article-title":"Meloxicam, 15 mg\/day, spares platelet function in healthy volunteers","volume":"66","author":"de Meijer","year":"1999","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2023.107251_bb0210","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MBC.0b013e32834ddf18","article-title":"Capsaicin-induced inhibition of platelet aggregation is not mediated by transient receptor potential vanilloid type 1","volume":"23","author":"Mittelstadt","year":"2012","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"6","key":"10.1016\/j.vascn.2023.107251_bb0215","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1254\/fpj.120.391","article-title":"Meloxicam (Mobic): A review of its pharmacological and clinical profile","volume":"120","author":"Ogino","year":"2002","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"25","key":"10.1016\/j.vascn.2023.107251_bb0220","doi-asserted-by":"crossref","first-page":"14583","DOI":"10.1073\/pnas.251543298","article-title":"A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin","volume":"98","author":"Ouellet","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.vascn.2023.107251_bb9064","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-3565(24)29580-X","article-title":"Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption","volume":"297","author":"Paulson","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"17","key":"10.1016\/j.vascn.2023.107251_bb0225","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1161\/01.CIR.0000145613.01188.0B","article-title":"Intravascular thrombosis after hypoxia-induced pulmonary hypertension: Regulation by cyclooxygenase-2","volume":"110","author":"Pidgeon","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.vascn.2023.107251_bb0230","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1172\/JCI0214752","article-title":"Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II","volume":"110","author":"Qi","year":"2002","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.vascn.2023.107251_bb0235","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1152\/physiolgenomics.00157.2006","article-title":"Divergent and convergent effects on gene expression and function in acute versus chronic endothelial activation","volume":"31","author":"Rajashekhar","year":"2007","journal-title":"Physiological Genomics"},{"issue":"9301","key":"10.1016\/j.vascn.2023.107251_bb0240","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(02)07370-1","article-title":"Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study","volume":"359","author":"Ray","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vascn.2023.107251_bb0245","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/0300985810364389","article-title":"Pathophysiology of cyclooxygenases in cardiovascular homeostasis","volume":"47","author":"Sellers","year":"2010","journal-title":"Veterinary Pathology"},{"issue":"3","key":"10.1016\/j.vascn.2023.107251_bb0250","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-007-0400-7","article-title":"Clinical use and pharmacological properties of selective COX-2 inhibitors","volume":"64","author":"Shi","year":"2008","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1016\/j.vascn.2023.107251_bb0255","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1165\/rcmb.2011-0190OC","article-title":"Inhibition of Pim1 kinase activation attenuates allergen-induced airway hyperresponsiveness and inflammation","volume":"46","author":"Shin","year":"2012","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"9","key":"10.1016\/j.vascn.2023.107251_bb0260","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","article-title":"Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects","volume":"41","author":"Simon","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"17","key":"10.1016\/j.vascn.2023.107251_bb0265","doi-asserted-by":"crossref","first-page":"11792","DOI":"10.1074\/jbc.M509292200","article-title":"Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways","volume":"281","author":"Syeda","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"issue":"11 Suppl","key":"10.1016\/j.vascn.2023.107251_bb0270","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.7556\/jaoa.1999.99.11.S13","article-title":"Celecoxib for the treatment of pain and inflammation: The preclinical and clinical results","volume":"99","author":"Tindall","year":"1999","journal-title":"The Journal of the American Osteopathic Association"},{"issue":"17","key":"10.1016\/j.vascn.2023.107251_bb0275","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMp048286","article-title":"Failing the public health--rofecoxib, Merck, and the FDA","volume":"351","author":"Topol","year":"2004","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.vascn.2023.107251_bb0280","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127000004001005","article-title":"Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers","volume":"40","author":"Van Hecken","year":"2000","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1016\/j.vascn.2023.107251_bb0285","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0002-8703(03)00398-3","article-title":"Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program","volume":"146","author":"Weir","year":"2003","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1016\/j.vascn.2023.107251_bb0290","first-page":"394","article-title":"Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor","volume":"55","author":"Yoshino","year":"2005","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1016\/j.vascn.2023.107251_bb0295","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nm1412","article-title":"Genetic model of selective COX2 inhibition reveals novel heterodimer signaling","volume":"12","author":"Yu","year":"2006","journal-title":"Nature Medicine"},{"issue":"132","key":"10.1016\/j.vascn.2023.107251_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003787","article-title":"Vascular COX-2 modulates blood pressure and thrombosis in mice","volume":"4","author":"Yu","year":"2012","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/j.vascn.2023.107251_bb0305","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/01.HYP.0000140924.91479.03","article-title":"Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension","volume":"44","author":"Zewde","year":"2004","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.vascn.2023.107251_bb0310","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0192623310378866","article-title":"Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury","volume":"38","author":"Zhang","year":"2010","journal-title":"Toxicologic Pathology"},{"issue":"1","key":"10.1016\/j.vascn.2023.107251_bb0315","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14302\/issn.2328-0182.japst-12-99","article-title":"Etodolac, a preferential COX-2 inhibitor, does not inhibit platelet aggregation in a randomized placebo-controlled trial","volume":"1","author":"Zoller","year":"2013","journal-title":"Journal of Advanced Pharmaceutical Science and Technology"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871923000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871923000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:05:49Z","timestamp":1761005149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871923000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":65,"alternative-id":["S1056871923000023"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2023.107251","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disconnect between COX-2 selective inhibition and cardiovascular risk in preclinical models","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2023.107251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107251"}}